Hey Spidey. You are a reasonable poster, with respect from me anyways, as to your thoughtful and helpful posts. Do you really think they can get conditional approval for CLI in 2018? That would mean they would have to be half enrolled by the end of this year, since they all have to be followed for a year after. That seems extremely unlikely. I think it's highly unlikely to get half enrolled by the end of 2018!!! IC trial was painstakingly slow, and it is approximately the same number.
And then there's the question of efficacy to go along with that. In essence they are just jumping from Phase 1 to Phase 3. Historically knocks out a vast majority of candidates. But that is a concern that should get answered either way come April with IC results.
Yes the government is their most viable option for some near term approval. But the longer this pivotal trial takes to get moving, the more worrisome it becomes. Six months of crickets on that one so far. What is going on? I wish something would be mentioned on this.
Much of everyone frustration comes from management's continued inability to inform shareholders of anything. Total garbage on their part. They can say they have enough funding for these trials, but I truly don't think so. Maybe they can if they activate their cost cutting contingency plan, but at the rate they're spending cash on these useless shows, that might not even do it.
Without government money for ARS, dilution will come without a doubt and it will be painful. There's no other way except partnership, and we all know how good they are at finding one of them.
